Inhibition of CD40L with Frexalimab in Multiple Sclerosis
New England Journal of Medicine · 15.02.2024 · 390 (7) · 589-600
DOI: 10.1056/nejmoa2309439 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift New England Journal of Medicine, erschienen am 15.02.2024. Verfasst von Patrick Vermersch und 13 weiteren Autor:innen. Beteiligte Einrichtung: From the University of Lille, INSERM Unité 1172, Lille Neuroscience and Cognition, Lille University Hospital, University Hospital Federation Precise,…. Hauptthemen laut MEDLINE: CD40 Ligand, Multiple Sclerosis, Relapsing-Remitting, Antibodies, Monoclonal, CD40 Antigens. Die Arbeit wurde bisher 114-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Sanofi.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- From the University of Lille, INSERM Unité 1172, Lille Neuroscience and Cognition, Lille University Hospital, University Hospital Federation Precise, Lille (P.V.), and Sanofi, Chilly-Mazarin (S.S., R.B., P.T.) - both in…
Förderung
- Sanofi
Zitieren
APA
Vermersch, P., Granziera, C., Mao-Draayer, Y., Cutter, G., Kalbus, O., Staikov, I., Dufek, M., Saubadu, S., Bejuit, R., Truffinet, P., Djukic, B., Wallstroem, E., Giovannoni, G., & Frexalimab Phase 2 Trial Group (2024). Inhibition of CD40L with Frexalimab in Multiple Sclerosis. New England Journal of Medicine, 390(7), 589-600. https://doi.org/10.1056/nejmoa2309439
Vancouver
Vermersch P, Granziera C, Mao-Draayer Y, Cutter G, Kalbus O, Staikov I, et al. Inhibition of CD40L with Frexalimab in Multiple Sclerosis. New England Journal of Medicine. 2024;390(7):589-600. doi:10.1056/nejmoa2309439
BibTeX
@article{Vermersch2024,
author = {Vermersch, Patrick and Granziera, Cristina and Mao-Draayer, Yang and Cutter, Gary and Kalbus, Oleksandr and Staikov, Ivan and Dufek, Michal and Saubadu, Stephane and Bejuit, Raphael and Truffinet, Philippe and Djukic, Biljana and Wallstroem, Erik and Giovannoni, Gavin and Frexalimab Phase 2 Trial Group, Frexalimab Phase 2 Trial Group},
title = {Inhibition of CD40L with Frexalimab in Multiple Sclerosis},
journal = {New England Journal of Medicine},
year = {2024},
volume = {390},
number = {7},
pages = {589--600},
doi = {10.1056/nejmoa2309439}
}
EUVIMED